Codiak BioSciences, Inc.
CDAKDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001659352
Codiak BioSciences, Inc. was delisted in 2023; its insiders filed their last Form 4 on Mar 30, 2023; 27 institutions reported holding it in 13F filings for Q1 2023, worth $1.52M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 27
- Q1 2023, −13 vs. previous quarter
- 13F value
- $1.52M
- Reported value at the end of Q1 2023
- Superinvestors holding
- 0
- At the end of Q1 2023
Superinvestors holding CDAK, Q1 2023
No superinvestor reported holding CDAK at the end of Q1 2023.
Latest insider trades
Open-market purchases and sales by Codiak BioSciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2023 (view filing)6:01 PM ET | Mar 30 | Same day | Howze YalondaSee Remarks | SSale | −1.63K | $0.1955 | −$318.27 | −17.9%7.46K after | |
| Mar 30, 2023 (view filing)5:19 PM ET | Mar 29 | 1 day | Sathyanarayanan SriramChief Scientific Officer | SSale | −11.8K | $0.1652 | −$1.94K | −100.0%0 after | |
| Mar 30, 2023 (view filing)5:13 PM ET | Mar 28 | 2 days | Konstantinov KonstantinChief Technology Officer | SSale | −9.36K | $0.2001 | −$1.87K | −100.0%0 after | 2 lots |
| Mar 30, 2023 (view filing)5:13 PM ET | Mar 28 | 2 days | Bain LindaChief Financial Officer | SSale | −13.4K | $0.1693 | −$2.27K | −100.0%0 after | |
| Mar 30, 2023 (view filing)5:12 PM ET | Mar 29 | 1 day | Barna NicoleSee Remarks | SSale | −7.30K | $0.1653 | −$1.21K | −60.1%4.85K after | 2 lots |
| Mar 30, 2023 (view filing)5:12 PM ET | Mar 28 | 2 days | Williams Douglas EPresident & CEO | SSale | −41.7K | $0.18 | −$7.50K | −84.5%7.66K after | |
| Feb 21, 2023 (view filing) | Aug 17, 2022-Feb 17, 2023 | 188 daysLate | Bain LindaChief Financial Officer | SSale | −4.93K | $1.37 | −$6.74K | −26.9%13.4K after | 2 lots |
| Feb 21, 2023 (view filing) | Aug 17, 2022-Feb 17, 2023 | 188 daysLate | Konstantinov KonstantinChief Technology Officer | SSale | −2.70K | $1.38 | −$3.71K | −26.6%7.43K after | 2 lots |
| Feb 21, 2023 (view filing) | Aug 17, 2022-Feb 17, 2023 | 188 daysLate | Williams Douglas EPresident & CEO | SSale | −14.8K | $1.37 | −$20.2K | −23.1%49.3K after | 2 lots |
| Feb 21, 2023 (view filing) | Aug 17, 2022-Feb 17, 2023 | 188 daysLate | Sathyanarayanan SriramChief Scientific Officer | SSale | −4.69K | $1.38 | −$6.47K | −28.5%11.8K after | 2 lots |
Top 10 13F holders, Q1 2023
The largest institutional positions in Codiak BioSciences, Inc. at the end of Q1 2023; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 3,540,636 | $617.8K | 0.02% | 00.0% | Unchanged |
| Laurion Capital Management LP | 2,013,300 | $351.3K | 0.02% | 00.0% | Unchanged |
| FMR LLC | 897,078 | $156.5K | 0.00% | −3,708,515−80.5% | Reduced |
| University of Texas/Texas Am Investment Managment Co | 847,108 | $148.0K | 0.06% | 00.0% | Unchanged |
| Vanguard Group Inc | 580,770 | $101.3K | 0.00% | −242,966−29.5% | Reduced |
| Ensign Peak Advisors, Inc | 252,782 | $44.1K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 161,957 | $28.0K | 0.00% | −138,854−46.2% | Reduced |
| Forefront Analytics, LLC | 110,210 | $19.2K | 0.01% | +10,275+10.3% | Added |
| Parametrica Management Ltd | 65,098 | $11.0K | 0.02% | 00.0% | Unchanged |
| Bank of America Corp | 53,055 | $9.23K | 0.00% | +4,483+9.2% | Added |